quinazolines has been researched along with enoximone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Aubioul, JA; de Chaffoy de Courcelles, DR; De Clerck, FF; Hermans, CF; Vandeplassche, GM; Wouters, LJ | 1 |
| Braunwald, E; Colucci, WS; Wright, RF | 1 |
| Chatterjee, K; Daly, PA; Kereiakes, D; Modin, G; Simonton, CA | 1 |
| Carlier, J; D'Orio, V; el Allaf, D | 1 |
| Kazmaier, S; Sonntag, H; Stephan, H | 1 |
| Ferrari, M; Foth, H; Hellige, G; Hering, JP; Schröder, T; Sipinková, I | 1 |
| Hoeft, A; Kazmaier, S; Sonntag, H; Stephan, H | 1 |
| de Chaffoy de Courcelles, D; Roevens, P | 1 |
2 review(s) available for quinazolines and enoximone
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Coenzymes; Enoximone; Heart; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Nifedipine; Oxyfedrine; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinazolines; Ubiquinone | 1986 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Time Factors; Xanthines | 1984 |
2 trial(s) available for quinazolines and enoximone
| Article | Year |
|---|---|
[Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122].
Topics: Adult; Aged; Anesthesia; Blood Pressure; Coronary Disease; Enoximone; Hemodynamics; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Quinazolines; Stroke Volume; Vascular Resistance | 1995 |
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Topics: Adult; Aged; Cardiotonic Agents; Catecholamines; Coronary Circulation; Enoximone; Heart; Hemodynamics; Humans; Imidazoles; Lactates; Lactic Acid; Male; Middle Aged; Myocardial Ischemia; Phosphodiesterase Inhibitors; Quinazolines; Vasodilator Agents; Ventricular Function, Left | 1994 |
4 other study(ies) available for quinazolines and enoximone
| Article | Year |
|---|---|
Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Topics: Analysis of Variance; Animals; Cardiotonic Agents; Dogs; Enoximone; Female; Heart Ventricles; Hemodynamics; Imidazoles; In Vitro Techniques; Isoenzymes; Male; Milrinone; Myocardial Contraction; Myocardial Reperfusion; Myocardium; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridones; Quinazolines | 1992 |
Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiotonic Agents; Death, Sudden; Drug Evaluation; Enoximone; Female; Heart Failure; Humans; Imidazoles; Male; Middle Aged; Milrinone; Pyridones; Quinazolines; Retrospective Studies; Time Factors | 1987 |
Peripheral and cardiac effects of a new phosphodiesterase inhibitor in comparison with enoximone.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Coronary Circulation; Enoximone; Heart; Heart Rate; Hemodynamics; Imidazoles; Myocardium; Oxygen Consumption; Phosphodiesterase Inhibitors; Quinazolines; Regional Blood Flow; Sheep; Vascular Resistance; Ventricular Pressure | 1994 |
Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminoquinolines; Blood Platelets; Calcium; Chlortetracycline; Cytosol; Enoximone; Heart; Homeostasis; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones; Quinazolines | 1993 |